Join
Live feed
·
PRReleasevia Quantisnow
INVO BioScience Inc. logo
NAYA Biosciences Inc. logo

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

ByQuantisnow·Wall Street's wire, on your screen.
INVO· INVO BioScience Inc.NAYA· NAYA Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INVO (INVO BioScience Inc.), NAYA (NAYA Biosciences Inc.) and more on Quantisnow.